





HIV Indicator       Female 95% CI     Male  95% CI  Total    95% CI
Annual incidence (%)      
  15–49 years    1.08  0.70-1.46    0.33  0.10-0.56 0.70 0.47-0.93
  15–59 years    1.00  0.65-1.36    0.33  0.11-0.56  0.66 0.45-0.88
Prevalence (%)      
  15–49 years    14.5  13.6-15.4     8.6  7.9-9.3  11.6 10.9-12.3
  15–59 years    14.9  14.0-15.8     9.5  8.8-10.3  12.3 11.6-13.0
  0-14 years    ---                 ---                    ---                 ---                 1.3 1.0-1.6
Viral load suppression (%)      
  15–59 years    61.3  58.7-63.8    57.5  53.5-61.5 59.8 57.4-62.2
95% CI (confidence interval) indicates the interval within which the true population parameter is expected to fall 95% of the time.
Viral load suppression is defined as HIV RNA <1,000 copies per ml of plasma among HIV-positive adults.
Annual incidence of HIV among adults ages 15 to 59 years in Zambia is 0.66 percent: 1.0 percent among females and 0.33 
percent among males. This corresponds to approximately 46,000 new cases of HIV annually among adults ages 15 to 59 
years in Zambia.
Prevalence of HIV among adults ages 15 to 59 years in Zambia is 12.3 percent: 14.9 percent among females and 9.5 percent 
among males. This corresponds to approximately 980,000 people living with HIV (PLHIV) ages 15 to 59 years in Zambia. 
Prevalence of viral load suppression (VLS) among HIV-positive adults ages 15 to 59 years in Zambia is 59.8 percent: 61.3 
percent among females and 57.5 percent among males.
The Zambia Population-Based HIV Impact 
Assessment (ZAMPHIA), a household-based 
national survey, was conducted between March 
and August 2016 in order to measure the status 
of Zambia’s national HIV response. ZAMPHIA offered HIV counseling and testing with return of results, and 
collected information about uptake of care and treatment services. This survey is the first in Zambia to measure 
national HIV incidence, pediatric HIV prevalence, and viral load suppression. The results provide information on 
national and subnational progress toward control of the HIV epidemic.
ZAMPHIA was led by the Government of Zambia through the Ministry of Health (MOH), conducted with funding 
from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and technical assistance through the U.S. 
Centers for Disease Control and Prevention (CDC). The survey was implemented by ICAP at Columbia University 
in collaboration with local partners, including the Central Statistical Office (CSO), the Tropical Disease Research 
Center (TDRC), the University Teaching Hospital (UTH), and the University of Zambia.
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Among adults ages 15 to 59 years, prevalence 
of HIV varies geographically across Zambia, 
ranging from 5.9 percent in Muchinga Province 
to 16.0 percent in Western Province and 16.1 
percent in Lusaka.
Province                  HIV Prevalence       95% CI
Central     13.4            11.1-15.8
Copperbelt     14.2                         12.7-15.8
Eastern      8.2                         6.1-10.4
Luapula     9.3                         6.8-11.8
Lusaka     16.1                         14.5-17.8
Muchinga    5.9                         4.2-7.7
Northern     9.7                         7.5-11.9
North Western    6.9                         5.6-8.2
Southern    13.4                         11.7-15.1
Western     16.0                         11.7-20.4
Prevalence of VLS among HIV-positive 
people in Zambia is highest among older 
adults: 73.5 percent among HIV-positive 
females and 73.0 percent among HIV-
positive males ages 45 to 59 years. In 
contrast, prevalence of VLS is distinctly 
lower among younger adults: 34.0 percent 
among HIV-positive females and 35.7 
percent among HIV-positive males ages  
15 to 24 years.
HIV prevalence peaks at 30.5 percent 
among females ages 40 to 44 years, as 
compared to 24.3 percent among males 
ages 45 to 49 years. The disparity in HIV 
prevalence by sex is most pronounced 
among young adults: HIV prevalence among 
20- to 24-year-olds is four times as high 
among females (8.6 percent) than males 
(2.1 percent).
HIV PREVALENCE, BY AGE AND SEX
HIV PREVALENCE AMONG ADULTS, BY PROVINCE
VIRAL LOAD SUPPRESSION AMONG HIV-POSITIVE PEOPLE, BY AGE AND SEX





































































































































Among HIV-positive adults ages 15 to 
59 years, prevalence of VLS varies 
geographically across Zambia, ranging from 
50.0 percent in Northern Province to 67.8 
percent in the Eastern Province.
VIRAL LOAD SUPPRESSION AMONG HIV-POSITIVE ADULTS, BY PROVINCE
ACHIEVEMENT OF THE 90-90-90 GOALS AMONG HIV-POSITIVE ADULTS, BY SEX 
Province VLS Prevalence      95% CI
Central  60.7                    53.5-67.9
Copperbelt  57.4                    52.2-62.7
Eastern   67.8                    60.1-75.4
Luapula  54.0                    38.7-69.3
Lusaka  63.4                    58.9-67.9
Muchinga 62.8                    53.2-72.5
Northern  50.0                    35.1-64.9
North Western 54.2                    46.3-62.0
Southern 63.7                    56.7-70.6
Western  50.1                    37.7-62.6
90–90–90: an ambitious treatment target to help end the AIDS epidemic 
By 2020, 90 percent of all PLHIV will know their HIV status; 90 percent of all people with diagnosed HIV infection will receive 
sustained antiretroviral therapy (ART); and 90 percent of all people receiving ART will have viral suppression.
Diagnosed
In Zambia, 67.3 percent of PLHIV ages 15 to 59 years 
report knowing their HIV status: 70.0 percent of HIV-
positive females and 62.8 percent of HIV-positive males 
know their HIV status.
On Treatment
Among PLHIV ages 15 to 59 years who know their HIV 
status, 85.4 percent self-report current use of ART: 84.9 
percent of HIV-positive females and 86.2 percent of 
HIV-positive males who know their HIV status self-report 





Among PLHIV ages 15 to 59 years who self-report 
current use of ART, 89.2 percent are virally suppressed: 
89.7 percent of HIV-positive females and 88.2 percent 
of HIV-positive males who self-report current use of 
ART are virally suppressed.
Error bars represent 
95% confidence intervals.












































































The PHIA Project is a multi-country project funded by PEPFAR to conduct national HIV-focused surveys that 
describe the status of the HIV epidemic. Results will measure important national and regional HIV-related 
parameters, including progress toward 90-90-90 goals, and will guide policy and funding priorities. ICAP at 
Columbia University is implementing the PHIA Project in close collaboration with CDC and other partners.  
See phia.icap.columbia.edu for more details.
This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of cooperative agreement 
#U2GGH001226. The contents of this document do not necessarily reflect the views of the United States Government. The results presented should be 
considered preliminary and are subject to change.
The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.
PREVALENCE OF HEPATITIS B VIRUS, BY SEX, AGE AND HIV STATUS
CONCLUSIONS
Among adults ages 15 to 59 years, prevalence 
of infection with hepatitis B virus (HBV) 
is higher among HIV-positive (7.1%) than 
HIV-negative (5.4%) adults. Among children 
ages 0 to 14 years, HBV infection is more 
prevalent among HIV-positive (5.2%) than 
HIV-negative (1.3%) children. Prevalence of 
HBV is especially high among HIV-positive 
males ages 15 to 59 years (10.2%).
Hepatitis B virus testing was conducted in 
each household using a serological hepatitis 
B surface antigen (HBsAg) rapid diagnostic 
test, which helps to diagnose acute infection 
and confirm chronic infection.
Of 12,310 eligible households, 89.0 percent completed a household interview. Of 13,326 eligible women and 11,349 
eligible men ages 15 to 59 years, 82.0 percent of women and 71.4 percent of men were both interviewed and tested for 
HIV. Of 11,669 eligible children ages 0 to 14 years, 68.2 percent were tested for HIV.
HIV prevalence testing was conducted in each household using a serological rapid diagnostic testing algorithm based 
on Zambia’s national guidelines, with laboratory confirmation of seropositive samples using a supplemental assay. A 
laboratory-based incidence testing algorithm (HIV-1 LAg avidity plus viral load) was used to distinguish recent from 
long-term infection, and incidence estimates were obtained using the CDC Incidence Calculator, which uses the formula 
recommended by the WHO Incidence Working Group and Consortium for Evaluation and Performance of Incidence Assays, 
with time cutoff (T)=1.0 year and residual proportion false recent (PFR)=0.00. Survey weights are utilized for all estimates.
RESPONSE RATES AND HIV TESTING METHODS










HIV Positive       
  0-14     8.1   2.9-13.3         2.8         0.0-6.9          5.2            1.9-8.5
  15-59    5.1   4.0-6.3         10.2         7.9-12.6          7.1             5.9-8.3
  0-59     5.3   4.2-6.4         9.3         7.1-11.5           6.9            5.8-8.0
HIV Negative       
  0-14     1.2   0.9-1.5         1.3         0.9-1.8          1.3               1.0-1.6
  15-59    3.9   3.5-4.3         6.9         6.2-7.6          5.4            5.0-5.8
  0-59     2.5   2.3-2.8         4.1         3.7-4.5          3.3            3.0-3.6
Total        
  0-14     1.3   1.0-1.6         1.4         1.0-1.8            1.3              1.1-1.6
  15-59    4.1   3.7-4.5         7.2         6.5-7.9          5.6             5.2-6.0
  0-59     2.8   2.5-3.0         4.4         3.9-4.8          3.6            3.3-3.8
TDRC
• Since 2004, Zambia’s HIV interventions have resulted in progress toward the UNAIDS’ targets of 90-90-90 (67-85-89). 
• The declining national HIV incidence depicts strides toward epidemic control. However, incidence among women
   remains unacceptably high.
• With the goal of an AIDS-free generation by 2030, continued expansion of HIV testing and treatment, especially for
   men and young women will play a central role.
•  Beyond this summary sheet, further analysis will shed light on HIV behaviors, services and treatment outcomes.
